Long Non-Coding RNAs as Epigenetic Regulators of Immune Checkpoints in Cancer Immunity

Cancers (Basel). 2022 Dec 28;15(1):184. doi: 10.3390/cancers15010184.

Abstract

In recent years, cancer treatment has undergone significant changes, predominantly in the shift towards immunotherapeutic strategies using immune checkpoint inhibitors. Despite the clinical efficacy of many of these inhibitors, the overall response rate remains modest, and immunotherapies for many cancers have proved ineffective, highlighting the importance of knowing the tumor microenvironment and heterogeneity of each malignancy in patients. Long non-coding RNAs (lncRNAs) have attracted increasing attention for their ability to control various biological processes by targeting different molecular pathways. Some lncRNAs have a regulatory role in immune checkpoints, suggesting they might be utilized as a target for immune checkpoint treatment. The focus of this review is to describe relevant lncRNAs and their targets and functions to understand key regulatory mechanisms that may contribute in regulating immune checkpoints. We also provide the state of the art on super-enhancers lncRNAs (selncRNAs) and circular RNAs (circRNAs), which have recently been reported as modulators of immune checkpoint molecules within the framework of human cancer. Other feasible mechanisms of interaction between lncRNAs and immune checkpoints are also reported, along with the use of miRNAs and circRNAs, in generating new tumor immune microenvironments, which can further help avoid tumor evasion.

Keywords: cancer immunity; circular RNA; epigenetic regulation; immune checkpoint; long non-coding RNAs.

Publication types

  • Review

Grants and funding

This research did not receive any specific grant from commercial or not-for-profit sectors. This work was supported by UV-La Fe 2022 Programa PROYECTOS DE INNOVACIÓN (Ref. InmunoDX).